Publications by authors named "M A Bekadja"
[Setting up haploidentical hematopoietic cell transplantation in low- and middle-income countries: The Recommendations of the Francophone Society of Bone Marrow and Cellular Therapy (SFGM-TC)].
Fati Hamzy Patrice Chevallier Bénédicte Bruno Valérie Coiteux Maria El Kababri Mohamed-Amine Bekadja
Bull Cancer
October 2024
Article Synopsis
- Haploidentical hematopoietic cell transplantation (haplo-HCT) is increasingly used globally but remains uncommon in low- and middle-income countries, prompting a working group from the SFGM-TC to propose recommendations for implementation.
- * The potential advantages of haplo-HCT include better accessibility to donors and lower costs; however, it should only be performed in experienced centers with a track record of related HLA-matched transplants.
- * Regular evaluations are necessary to monitor the feasibility and outcomes of implementing haplo-HCT in these regions, particularly for patients lacking HLA-matched donors.*
Article Synopsis
- Autologous peripheral blood stem cell (PBSC) transplantation is a common treatment for conditions like multiple myeloma and lymphomas, and it usually involves freezing the stem cells before transplant.* -
- A recent systematic review of 19 transplant centers that performed non-cryopreserved PBSC transplants showed that the procedure is feasible and safe, with high stem cell viability and low rates of complications.* -
- The study found that stem cell viability was over 90% for multiple myeloma and over 75% for lymphomas, with quick engraftment times, and only 1% transplant-related mortality within 100 days.*
Management of acquired aplastic anemia (AA) in emerging countries depends on the means of prognostic stratification, treatment and logistics available. During the 13th annual harmonization workshop of the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC), a designated working group reviewed the literature in order to elaborate unified guidelines for allogeneic hematopoietic cell transplantation (Allo-HCT) in this disease. In terms of practice, the conclusions are as follows; The use of anti-tymocyte globuline (ATG) is mainly from rabbit and very little from horse.
View Article and Find Full Text PDFArticle Synopsis
- Autologous hematopoietic cell transplantation (AHCT) is an effective treatment for multiple myeloma, with real-world data collected from 61,725 patients revealing median overall survival of 90.2 months and median progression-free survival of 36.5 months.* -
- Cumulative relapse incidence and non-relapse mortality rates at 24 months were found to be 33% and 2.5% respectively, with better outcomes linked to factors like younger age, certain disease subtypes, and high performance status.* -
- Global variations were observed in patient outcomes based on registry data, influenced by differences in patient characteristics, use of maintenance treatments, and macroeconomic factors, highlighting the safety and effectiveness of AH
Recommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group.
Jérôme Paillassa Elsa Maitre Nadia Belarbi Boudjerra Abdallah Madani Raihane Benlakhal Mohammed Amine Bekadja
Cancers (Basel)
June 2024
Article Synopsis
- Hairy-cell leukemia (HCL) is a rare blood cancer that has improved prognosis due to treatments like purine nucleoside analogs, but some patients experience relapses and chemotherapy resistance.
- Recent advances in understanding HCL's genetic and cellular mechanisms have led to the development of targeted therapies, including BRAF and MEK inhibitors.
- Updated guidelines emphasize the importance of BRAF mutation for diagnosis, the relevance of certain immunoglobulin mutations for prognosis, and recommend strategies for managing both HCL and similar disorders.